However, a recent study in a mouse tumor model found that intermittent administration of a MEK inhibitor combined with GITR and OX40 co-stimulation significantly enhanced T-cell function and decreased tumor growth [31▪▪], highlighting the complexity and context-dependency of co-stimulatory targeting. The gene discussed is MAP2K7; the disease is neoplasm.